$NBIO The patent will be issued on Nov. 8: "This issuance strengthens our growing IP portfolio in our brain cancer treatment using Pritumumab, a unique natural antibody that crosses the blood brain barrier," said Nascent CEO Sean Carrick. https://seekingalpha.com/news/3898553-nascent...pritumumab